Cytokines and biological response modifiers in the treatment of infection

  • Brigitta U. Mueller
  • Phillip A. Pizzo
Part of the Cancer Treatment and Research book series (CTAR)


Patients undergoing myelosuppressive cancer therapy (chemotherapy or radiation) are at an increased risk to develop potentially life-threatening infections. The incidence appears to be strongly correlated with the duration and degree of absolute neutropenia [1]. A neutrophil count of <500 cells/mm3, and especially of <100 cells/mm3, carries an increased risk for fever and bacterial infections, and a prolonged duration of neutropenia increases the risk for fungal and other infectious complications [2, 3, 4, 5, 6].


Febrile Neutropenia Chronic Granulomatous Disease Biological Response Modifier Congenital Neutropenia Intensive Induction Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infections in patients with acute leukemia. Ann Intern Med 1966:64:328–340.PubMedGoogle Scholar
  2. 2.
    Pizzo PA. Infectious complications in the child with cancer. I. Pathophysiology of the compromised host and the initial evaluation and management of the febrile cancer patient. J Pediatr 1981;98:341–354.PubMedGoogle Scholar
  3. 3.
    Pizzo PA. Considerations for the prevention of infectious complications in patients with cancer. Rev Infect Dis 1989;11(Suppl. 7):S1551–S1563.PubMedGoogle Scholar
  4. 4.
    Richet HM, Andremont A, Tancrede C, Pico JL, Jarvis WR. Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 1991;13:211–215.PubMedGoogle Scholar
  5. 5.
    Wingard JR, Santos GW, Saral R. Differences between first and subsequent fevers during prolonged neutropenia. Cancer 1987;59:844–849.PubMedGoogle Scholar
  6. 6.
    Chanock S. Evolving risk factors for infectious complications of cancer therapy. In: Pizzo PA, ed. Hematology/Oncology Clinics of North America. Philadelphia: W.B. Saunders, 1993;7:4:771–794.Google Scholar
  7. 7.
    Frost JD, Sondel PM. Immunotherapy for infection and malignancy in children with cancer. Adv Pediatr 1994;41:385–413.PubMedGoogle Scholar
  8. 8.
    American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471–2508.Google Scholar
  9. 9.
    Yim JM, Matuszewski KA, Vermeulen LC Jr., Ratko TA, Burnett DA, Vlasses PH. Surveillance of colony-stimulating factor use in US academic health centers. Ann Pharmacother 1995;29:475–481.PubMedGoogle Scholar
  10. 10.
    Paul WE, Seder RA. Lymphocyte response and cytokines. Cell 1994;76:241–251.PubMedGoogle Scholar
  11. 11.
    Groopman JE, Molina J-M, Scadden DT. Hematopoietic growth factors. Biology and clinical applications. N Engl J Med 1989;321:1449–1459.PubMedGoogle Scholar
  12. 12.
    Roilides E, Pizzo PA. Biologicals and hematopoietic cytokines in prevention or treatment of infections in immunocompromised hosts. In: Pizzo PA, ed. Infectious Complications in the Immunocompromised Host. Philadelphia: W.B. Saunders, 1993;7:4:841–864.Google Scholar
  13. 13.
    Bocci V. Interleukins. Clinical pharmacokinetics and practical implications. Clin Pharmacokinet 1991;21:274–284.PubMedGoogle Scholar
  14. 14.
    O’Garra A. Interleukins and the immune system 1. Lancet 1989;1:943–947.PubMedGoogle Scholar
  15. 15.
    O’Garra A. Interleukins and the immune system 2. Lancet 1989;1:1003–1005.PubMedGoogle Scholar
  16. 16.
    Hill HR. Modulation of host defense with interferon-g in pediatrics. J Infect Dis 1993;167(Suppl. 1):S23–S28.PubMedGoogle Scholar
  17. 17.
    Souza LM, Boone TC, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK, Barendt J, Platzer E, Moore MAS, Mertelsmann R, Weite K. Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science 1986;232:61–65.PubMedGoogle Scholar
  18. 18.
    Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. First part. N Engl J Med 1992;327:28–35.PubMedGoogle Scholar
  19. 19.
    Wang JM, Chen ZG, Colella S, Bonilla MA, Weite K, Bordignon C, Mantovani A. Chemo-tactic activity of recombinant human granulocyte colony-stimulating factor. Blood 1988;72:1456–1460.PubMedGoogle Scholar
  20. 20.
    Roilides E, Walsh TJ, Pizzo PA, Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991;163:579–583.PubMedGoogle Scholar
  21. 21.
    Nelson S. Role of granulocyte colony-stimulating factor in the immune response to acute bacterial infection in the nonneutropenic host: An overview. Clin Infect Dis 1994;18(Suppl. 2):S197–S204.PubMedGoogle Scholar
  22. 22.
    Kerst JM, de Haas M, van der Schoot CE, Slaper-Cortenbach ICM, Kleijer M, von dem Borne AEGK, van Oers RHJ. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: Induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells. Blood 1993;82:3265–3272.PubMedGoogle Scholar
  23. 23.
    Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, Sheridan WP, Kefford RF, Cebon J, Olver I, McKendrick J, Toner G, Bradstock K, Lieschke M, Cruiskank S, Tomita DK, Hoffman EW, Fox RM, Morstyn G. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994;121:492–501.PubMedGoogle Scholar
  24. 24.
    Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987;56:809–813.PubMedGoogle Scholar
  25. 25.
    Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vincent M, Stewart M, Glaspy J. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164–170.PubMedGoogle Scholar
  26. 26.
    Chevallier B, Chollet P, Merrouche Y, Roche H, Fumoleau P, Kerbrat P, Genot JY, Fargeot P, Olivier JP, Fizames C, Clavel M, Yver A, Chabernaud VC. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13:1564–1571.PubMedGoogle Scholar
  27. 27.
    Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y, Hirano M, Yokomaku S, Nakayama S, Yoshida Y, Miura AB, Morishima Y, Dohy H, Niho Y, Hamajima N, Takaku F. Effect of granulocyte colony-stimulating factor after intensive induction in relapsed or refractory acute leukemia. N Engl J Med 1990;323:871–877.PubMedGoogle Scholar
  28. 28.
    Locatelli F, Zecca M, Ponchio L, Beguin Y, Giorgiani G, Maccario R, Bonetti F, De Stefano P, Cazzola M. Pilot trial of combined administration of erythropoietin and granulocyte colony-stimulating factor to children undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1994;14:929–935.PubMedGoogle Scholar
  29. 29.
    Miles SA, Mitsuyasu RT, Lee K, Moreno J, Alton K, Egrie JC, Souza L, Glaspy JA. Recombinant human granulocyte colony-stimulating factor increases circulating burst forming unit-erythron and red blood cell production in patients with severe human immunodeficiency virus infection. Blood 1990;75:2137–2142.PubMedGoogle Scholar
  30. 30.
    Miles SA, Golde DW, Mitsuyasu RT. The use of hematopoietic hormones in HIV infection and AIDS-related malignancies. In: Mitsuyasu RT, Golde DW, ed. Hematol/Oncol Clin North Amer. Philadelphia: W.B. Saunders, 1991, pp. 267–280.Google Scholar
  31. 31.
    Weston B, Axtell RA, Todd RF III, Vincent M, Balazovich KJ, Suchard SJ, Boxer LA. Clinical and biologic effects of granulocyte colony-stimulating factor in the treatment of myelokathexis. J Pediatr 1991;118:229–234.PubMedGoogle Scholar
  32. 32.
    Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J, Wang W, Jakubowski A, Winton E, Lalezari P, Robinson W, Glaspy JA, Emerson S, Gabrilove J, Vincent M, Boxer LA. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (Filgrastim) for treatment of severe chronic neutropenia. Blood 1993;81:2496–2502.PubMedGoogle Scholar
  33. 33.
    Hammond WP, Price TH, Souza LM, Dale DC. Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med 1989;320:1306–1311.PubMedGoogle Scholar
  34. 34.
    Bonilla MA, Gillio AP, Ruggeiro M, Kernan NA, Brochstein JA, Abboud M, Fumagalli L, Vincent M, Gabrilove JL, Weite K, Souza LM, O’Reilly RJ. Effects of recombinant granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med 1989;320:1574–1580.PubMedGoogle Scholar
  35. 35.
    Negrin RS, Haeuber DH, Nagler A, Olds LC, Donlon T, Souza LM, Greenberg PL. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I—II trial. Ann Intern Med 1989;110:976–984.PubMedGoogle Scholar
  36. 36.
    Kearns CM, Wang WC, Stute N, Ihle JN. Evans WE. Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia. J Pediatr 1993;123:471–479.PubMedGoogle Scholar
  37. 37.
    Kojima S, Tsuchida M, Matsuyama T. Myelodysplasia and leukemia after treatment of aplastic anemia with G-CSF. N Engl J Med 1992;326:1294–1295.PubMedGoogle Scholar
  38. 38.
    Imashuku S, Hibi S, Nakajima F, Mitsui T, Yokoyama S, Kojima S, Matsuyama T, Nakahata T, Ueda K, Tsukimoto I, et al. A review of 125 cases to determine the risk of myelodysplasia and leukemia in pediatrie neutropenic patients after treatment with recombinant human granulocyte colony-stimulating factor. Blood 1994;84:2380–2381.PubMedGoogle Scholar
  39. 39.
    Imashuku S, Hibi S, Kataoka-Morimoto Y, Yoshihara T, Ikushima S, Morioka Y, Todo S. Myelodysplasia and acute myeloid leukaemia in cases of aplastic anaemia and congenital neutropenia following G-CSF administration. Br J Haematol 1995;89:188–190.PubMedGoogle Scholar
  40. 40.
    Meropol NJ, Miller LD, Korn EL, Braitman LE, Macdermott ML, Schuchter LM. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992;84:1201–1204.PubMedGoogle Scholar
  41. 41.
    Broxmeyer HE, Benninger L, Patel SR, Benjamin RS, Vadhan-Raj S. Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor. Exp Hematol 1994;22:100–102.PubMedGoogle Scholar
  42. 42.
    Ohno R, Tomonaga M, Ohshima T, Masaoka T, Asou N, Oh H, Nishikawa K, Kanamaru A, Murakami H, Furusawa S, Japan Adult Leukemia Study Group. A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Int J Hematol 1993;58:73–81.PubMedGoogle Scholar
  43. 43.
    Butler RD, Waites TM, Lamar RE, Hainsworth JD, Greco FA, Johnson DH. Timing of G-CSF administration during intensive chemotherapy for breast cancer. ASCO, Anaheim, CA, 1992, p. 403.Google Scholar
  44. 44.
    Dührsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074–2081.PubMedGoogle Scholar
  45. 45.
    Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: A randomized controlled trial. Blood 1992;80:1430–1436.PubMedGoogle Scholar
  46. 46.
    Ottmann OG, Hoelzer D, Gracien E, Ganser A, Kelly K. Reutzel R, Lipp T, Busch FW, Schwonzen M, Heil G, et al. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: A randomized phase III trial. Blood 1995;86:444–450.PubMedGoogle Scholar
  47. 47.
    Liang D-C, Chen S-H, Lean S-F. Role of granulocyte colony-stimulating factor as adjunct therapy for septicemia in children with acute leukemia. Am J Hematol 1995;48:76–81.PubMedGoogle Scholar
  48. 48.
    Park JW, Mehrotra B, Barnett BO, Baron AD, Venook AP. The Sweet syndrome during therapy with granulocyte colony-stimulating factor. Ann Intern Med 1992;116:996–998.PubMedGoogle Scholar
  49. 49.
    Samlaska CP, Noyes DK. Localized cutaneous reactions to granulocyte colony-stimulating factor. Arch Dermatol 1993;129:645–646.PubMedGoogle Scholar
  50. 50.
    Ross HJ, Moy LA, Kaplan R, Figlin RA. Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment. Cancer 1991;68:441–443.PubMedGoogle Scholar
  51. 51.
    Glaspy JA, Baldwin GC, Robertson PA, Souza L, Vincent M, Ambersley J, Golde DW. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 1988;109:789–795.PubMedGoogle Scholar
  52. 52.
    Schliesser G, Pralle H, Lohmeyer J. Leukocytoclastic vasculitis complicating granulocyte colony-stimulating factor (G-CSF) induced neutrophil recovery in Tg-lymphocytosis with severe neutropenia. Ann Hematol 1992;65:151–152.PubMedGoogle Scholar
  53. 53.
    Ostlere LS, Harris D, Prentice HG, Rustin MHA. Widespread folliculitis induced by human granulocyte colony-stimulating factor therapy. Br J Dermatol 1992:127:193–194.PubMedGoogle Scholar
  54. 54.
    Jaiyesimi I, Giralt SS, Wood J. Subcutaneous granulocyte colony-stimulating factor and acute anaphylaxis. N Engl J Med 1991;325:587.PubMedGoogle Scholar
  55. 55.
    Lindemann A, Herrmann F, Oster W, Haffner G, Meyenburg W, Souza LM, Mertelsmann R. Hematologie effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 1989;74:2644–2651.PubMedGoogle Scholar
  56. 56.
    Wun T. The Felty syndrome and G-CSF-associated thrombocytopenia and severe anemia. Ann Intern Med 1993;118:318–319.PubMedGoogle Scholar
  57. 57.
    Mueller BU, Jacobsen F, Butler KM, Husson RN, Lewis LL, Pizzo PA. Combination treatment with azidothymidine and granulocyte colony-stimulating factor in children with human immunodeficiency virus infection. J Pediatr 1992:121:797–802.PubMedGoogle Scholar
  58. 58.
    Litam PP, Friedman HD, Loughran TP Jr. Splenic extramedullary hematopoiesis in a patient receiving intermittently administered granulocyte colony-stimulating factor. Ann Intern Med 1993:118:954–955.PubMedGoogle Scholar
  59. 59.
    Mueller BU, Burt R, Gulick L, Jacobsen F, Pizzo PA, Horne M. Disseminated intravascular coagulation associated with granulocyte colony-stimulating factor therapy in a child with human immunodeficiency virus infection. J Pediatr 1995;126:749–752.PubMedGoogle Scholar
  60. 60.
    Fleischmann J, Golde DW. Weisbart RH, Gasson JC. Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood 1986;68:708–711.PubMedGoogle Scholar
  61. 61.
    Baldwin GC, Gasson JC, Quan SG, Fleischmann J, Weisbart R, Oette D, Mitsuyasu RT, Golde DW. Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients. Proc Natl Acad Sci USA 1988;85:2763–2766.PubMedGoogle Scholar
  62. 62.
    Lopez AF, Williamson DJ, Gamble JR, Begley CG, Harlan JM, Klebanoff SJ, Waltersdorph A, Wong G, Clark SC, Vadas MA. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 1986;78:1220–1228.PubMedGoogle Scholar
  63. 63.
    Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074–2081.PubMedGoogle Scholar
  64. 64.
    Roilides E, Holmes A, Blake C, Venzon D, Pizzo PA, Walsh TJ. Antifungal activity of elutriated human monocytes agains Aspergillus fumigatus hyphae: Enhancement by granulocyte-macrophage colony-stimulating factor and interferon-g. J Infect Dis 1994; 170:894–899.PubMedGoogle Scholar
  65. 65.
    Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E, Schnipper LE. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988;319:593–598.PubMedGoogle Scholar
  66. 66.
    Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Sillaber C, Haas O, Vieder L, Maurer D, Schulz G, Speiser W, Geissler K, Kier P, Hinterberger W, Lechner K. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991;77:700–711.PubMedGoogle Scholar
  67. 67.
    Bunn PA Jr., Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995;13:1632–1641.PubMedGoogle Scholar
  68. 68.
    Bajorin DF, Nichols CR, Schmoll HJ, Kantoff PW, Bokemeyer C, Demetri GD, Einhorn LH, Bosl GJ. Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: A randomized trial. J Clin Oncol 1995;13:79–86.PubMedGoogle Scholar
  69. 69.
    Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F, Kaiser G. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma. J Clin Oncol 1994:12:2667–2676.PubMedGoogle Scholar
  70. 70.
    Engelhard M, Gerhartz H, Brittinger G, et al. Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin’s lymphomas: Results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/-rhGM-CSF. Ann Oncol 1994;5(Suppl. 2):123–125.PubMedGoogle Scholar
  71. 71.
    Laughlin MJ, Kirkpatrick G, Sabiston N, Peters W, Kurtzberg J. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF. Ann Hematol 1993;67:267–276.PubMedGoogle Scholar
  72. 72.
    Gerhartz HH, Engelhard M, Meusers P, et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin’s lymphomas. Blood 1993:82:2329–2339.PubMedGoogle Scholar
  73. 73.
    Chi K-H, Chen C-H, Chan W-K, Chow K-C, Chen S-Y, Yen S-H, Chao JY, Chang C-Y, Chen KY. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 1995;13:2620–2628.PubMedGoogle Scholar
  74. 74.
    Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast RC, Gilbert CJ, Oette DH. Effect of recombinant granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplant. N Engl J Med 1988;318:869–876.PubMedGoogle Scholar
  75. 75.
    Advani R. Chao NJ, Horning SJ, Blume KG, Ahn DK, Lamborn KR. Fleming NC, Bonnern EM, Greenberg PL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Intern Med 1992;116:183–189.PubMedGoogle Scholar
  76. 76.
    Gordon B, Spadinger A, Hodges E. Ruby E, Stanley R, Coccia P. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. J Clin Oncol 1994;12:1917–1922.PubMedGoogle Scholar
  77. 77.
    Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, Onetto N, Gillis S, Oette D, Gold M, Buckner CD, Hansen JA, Ritz J, Appelbaum FR, Armitage JO, Nadler LM. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773–1778.PubMedGoogle Scholar
  78. 78.
    Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;15:949–954.PubMedGoogle Scholar
  79. 79.
    Riikonen P, Saarinen UM, Mäkipernaa A, Hovi L, Komulainen A, Pikhala J, Jalanko H. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: A double blind placebo-controlled study in children. Pediatr Infect Dis J 1994;13:197–202.PubMedGoogle Scholar
  80. 80.
    Gluck S, Gagnon A. Neutropenic fever in patients after high-dose chemotherapy followed by autologous haematopoietic progenitor cell transplantation and human recombinant granulocyte-macrophage colony stimulating factor. Bone Marrow Transplant 1994;14:989–990.PubMedGoogle Scholar
  81. 81.
    Lieschke GJ, Cebon J, Morstyn G. Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989;74:2634–2643.PubMedGoogle Scholar
  82. 82.
    Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Second part. N Engl J Med 1992;327:99–106.PubMedGoogle Scholar
  83. 83.
    Roilides E, Mertins S, Eddy J, Walsh TJ, Pizzo PA, Rubin M. Impairment of neutrophil chemotactic and bactericidal function in children infected with human immunodeficiency virus type 1 and partial reversal after in vitro exposure to granulocyte-macrophage colony-stimulating factor. J Pediatr 1990;117:531–540.PubMedGoogle Scholar
  84. 84.
    Roilides E, Pizzo PA. Modulation of host defense by cytokines: Evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis 1992:15:508–524.PubMedGoogle Scholar
  85. 85.
    Nemunaitis J, Meyers JD, Buckner CD, Shannon-Dorcy K, Mori M, Shulman H, Bianco JA, Higano CS, Groves E, Storb R, Hansen J, Appelbaum FR, Singer JW. Phase I trial of recombinant macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991;78:907–913.PubMedGoogle Scholar
  86. 86.
    Cenci E, Bartocci A, Puccetti P, Mocci S, Stanley ER, Bistoni F. Macrophage colony-stimulating factor in murine candidiasis: Serum and tissue levels during infection and protective effect of exogenous administration. Infect Immun 1991:59:868–872.PubMedGoogle Scholar
  87. 87.
    Khwaja A, Johnson B, Addison IE, Yong K, Ruthven K, Abramson S, Linch DC. In vivo effects of macrophage colony-stimulating factor on human monocyte function. Br J Haematol 1991;77:25–31.PubMedGoogle Scholar
  88. 88.
    Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, Meyers J, Owens A, Day R, Ando D, O’Neill C, Buckner D, Singer J. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 1993;82:1422–1427.PubMedGoogle Scholar
  89. 89.
    Starnes HFJ. Biological effects and possible clinical applications of interleukin-1. Sem Hematol 1991;28:34–41.Google Scholar
  90. 90.
    D’Hondt V, Weynants P, Humblet Y, Guillaume T, Canon J-L, Beauduin M, Duprez P, Longueville J, Müll R, Chatelain C, Symann M. Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study. J Clin Oncol 1993;11:2063–2071.PubMedGoogle Scholar
  91. 91.
    Geissler K, Forstinger C, Kalhs P, Knöbl P, Kier P, Kyrle P, Lechner K. Effect of interleukin-3 on responsiveness to granulocyte colony-stimulating factor in severe aplastic anemia. Ann Intern Med 1992;117:223–225.PubMedGoogle Scholar
  92. 92.
    Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993;328:106–114.PubMedGoogle Scholar
  93. 93.
    Broudy VC, Kaushansky K, Harlan JM, Adamson JW. Interleukin 1 stimulates human endothelial cells to produce granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor. J Immunol 1987;139:464–468.PubMedGoogle Scholar
  94. 94.
    Fibbe WE, Van Damme J, Billiau A, Duinkerken N, Lurvink E, Ralph P, Altrock BW, Kaushansky K, Willemze R, Falkenburg JH. Human fibroblasts produce granulocyte-CSF, macrophage-CSF, and granulocyte-macrophage-CSF following stimulation by interleukin-1 and poly(rI).poly(rC). Blood 1988;72:860–866.PubMedGoogle Scholar
  95. 95.
    Fibbe WE, Daha MR, Hiemstra PS, Duinkerken N, Lurvink E, Ralph P, Altrock BW, Kaushansky K, Willemze R, Falkenburg JH. Interleukin 1 and poly(rI).poly(rC) induce production of granulocyte CSF, macrophage CSF, and granulocyte-macrophage CSF by human endothelial cells. Exp Hematol 1989;17:229–234.PubMedGoogle Scholar
  96. 96.
    Crown J, Jakubowski A, Gabrilove J. Interleukin-1: Biological effects in human hematopoiesis. Leuk Lymphoma 1993;9:433–440.PubMedGoogle Scholar
  97. 97.
    Kovacs CJ, Harrell JP, Gooya JM, Evans MJ, Johnke RM. Synergy between recombinant human IL-1 alpha (rHuIL-1) and M-CSF (rHuM-CSF) during the recovery of murine hematopoietic activity in myelosuppressed animals: abbreviated versus chronic administration of rHuM-CSF. Exp Hematol 1992;20:582–589.PubMedGoogle Scholar
  98. 98.
    Gallicchio VS, Hulette BC, Messino MJ, Gass C, Bieschke MW, Doukas MA. Effect of various interleukins (IL-1, IL-2, and IL-3) on the in vitro radioprotection of bone marrow progenitors (CFU-GM and CFU-MEG). J Biol Response Modif 1989;8:479–487.Google Scholar
  99. 99.
    Gallicchio VS, Shedlofsky SI, Swim AT, Robinson JM, Hulette BC, Messino MJ, Doukas MA. Modulation of murine hematopoiesis in vivo with recombinant murine interleukin-1. J Biol Response Modif 1989;8:422–439.Google Scholar
  100. 100.
    Johnson CS, Keckler DJ, Topper MI, Braunschweiger PG, Furmanski P. In vivo hematopoietic effects of recombinant interleukin-1 alpha in mice: Stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 1989;73: 678–683.PubMedGoogle Scholar
  101. 101.
    Castelli MP, Black PL, Schneider M, Pennington R, Abe F, Talmadge JE. Protective, restorative, and therapeutic properties of recombinant human IL-1 in rodent models. J Immunol 1988;140:3830–3837.PubMedGoogle Scholar
  102. 102.
    Neta R, Oppenheim JJ, Wang JM, Snapper CM, Moorman MA, Dubois CM. Synergy of IL-1 and stem cell factor in radioprotection of mice is associated with IL-1 upregulation of mRNA and protein expression for c-kit on bone marrow cells. J Immunol 1994;153:1536–1543.PubMedGoogle Scholar
  103. 103.
    Ozaki Y, Ohashi T, Kume S. Potentiation of neutrophil function by recombinant DNS-produced interleukin la. J Leukoc Biol 1987;42:621–627.PubMedGoogle Scholar
  104. 104.
    Ozaki Y, Ohashi T, Minami A, Nakamura S. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1 a. Infect Immun 1987;55:1436–1440.PubMedGoogle Scholar
  105. 105.
    Minami A, Fujimoto K, Ozaki Y, Nakamura S. Augmentation of host resistance to microbial infections by recombinant human interleukin-1 alpha. Infect Immun 1988;56:3116–3120.PubMedGoogle Scholar
  106. 106.
    Smith JWd, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 1992;10:1141–1152.PubMedGoogle Scholar
  107. 107.
    Kullberg BJ, van’ tWout JW, Poell RJ, van Furth R. Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice. Antimicrob Agents Chemother 1992;36:1225–1229.PubMedGoogle Scholar
  108. 108.
    van der Meer JW, Vogels MT, Kullberg BJ. Interleukin-1 and related pro-inflammatory cytokines in the treatment of bacterial infections in neutropenic and non-neutropenic animals. Biotherapy 1994;7:161–167.PubMedGoogle Scholar
  109. 109.
    Dinarello CA. The role of interleukin-1 in host responses to infectious diseases. Infect Agents Dis 1992;1:227–236.PubMedGoogle Scholar
  110. 110.
    Marley S, Reilly I, Russell N. Interleukin 1 has positive and negative regulatory effects in human long-term bone marrow culture. Exp Hematol 1992;20:75–79.PubMedGoogle Scholar
  111. 111.
    Sunderland MC, Roodman GD. Interleukin-3. Its biology and potential uses in pediatric hematology oncology. Am J Pediatr Hematol Oncol 1991;13:414–425.PubMedGoogle Scholar
  112. 112.
    Donahue RE, Seehra J, Metzger M, et al. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 1988;241:1820–1823.PubMedGoogle Scholar
  113. 113.
    Leary AG, Ikebuchi K, Hirai Y, Wong GG, Yang YC, Clark SC, Ogawa M. Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: Comparison with interleukin-1 alpha. Blood 1988;71:1759–1763.PubMedGoogle Scholar
  114. 114.
    Bhalla K, Tourkina E, Huang Y, Tang C, Mahoney ME, Ibrado AM. Effect of hemopoietic growth factors G-CSF and pIXY 321 on the activity of high dose ara-C in human myeloid leukemia cells. Leuk Lymphoma 1993;10(Suppl):123–131.PubMedGoogle Scholar
  115. 115.
    McCrady CW, Li F, Pettit GR, Grant S. Modulation of the activity of a human granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) by the macro-cyclic lactone protein kinase C activator bryostatin 1. Exp Hematol 1993;21:893–900.PubMedGoogle Scholar
  116. 116.
    Murray HW. Interferon-g, the activated macrophage, and host defense against microbial challenge. Ann Intern Med 1988;108:595–608.PubMedGoogle Scholar
  117. 117.
    Murray HW. Gamma interferon, cytokine-induced macrophage activation, and antimicrobial host defense. In vitro, in animal models, and in humans. Diagn Microbiol Infect Dis 1990:13:411–421.PubMedGoogle Scholar
  118. 118.
    Gallin JI, Farber JM, Holland SM, Nutman TB. Interferon-g in the management of infectious diseases. Ann Intern Med 1995;123:216–224.PubMedGoogle Scholar
  119. 119.
    Quie PG. Chronic granulomatous disease of childhood: A saga of discovery and understanding. Pediatr Infect Dis J 1993;12:395–398.PubMedGoogle Scholar
  120. 120.
    The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991;324:509–516.Google Scholar
  121. 121.
    Squires KE, Murphy WF, Madoff LC, Murray HW. Interferon-g and Mycobacterium avium-intracellulare infection. J Infect Dis 1989;159:599–600.PubMedGoogle Scholar
  122. 122.
    Schmid GP, Smith RP, Baltch AL, Hall CA, Schiffman G. Antibody response to pneumococcal vaccine in patients with multiple myeloma. J Infect Dis 1981;143:590–597.PubMedGoogle Scholar
  123. 123.
    Siber GR, Gorham C, Martin P, Corkery JC, Schiffman G. Antibody response to pretreatment immunization and post-treatment boosting with bacterial polysaccharide vaccines in patients with Hodgkin’s disease. Ann Intern Med 1986;104:467–475.PubMedGoogle Scholar
  124. 124.
    Centers for Disease Control. Recommendations of the Immunization Practices Advisory Committee (ACIP): Pneumococcal polysaccharide vaccine. MMWR 1989;••:64–76.Google Scholar
  125. 125.
    Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med 1989:320:892–897.PubMedGoogle Scholar
  126. 126.
    Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group [see comments]. N Engl J Med 1991:325:1545–1550.PubMedGoogle Scholar
  127. 127.
    Ruiz-Moreno M, Garcia R, Rua MJ, Serrano B, Moraleda G, Feijoo E, Bartolomé J, Ortiz F, Castillo I, Carreno V. Levamisole and interferon in children with chronic hepatitis B. Hepatology 1993;18:264–269.PubMedGoogle Scholar
  128. 128.
    Hersh EM, Brewton G, Abrams D, Bartlett J, Galpin J, Gill P, Gorter R, Gottlieb M, Jonikas JJ, Landesman S, Levine A, Marcel A, Petersen EA, Whiteside M, Zahradnik J, Negron C, Boutitie F, Caraux J, Dupuy J-M, Salmi R. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomaytic HIV infection and AIDS. JAMA 1991;265:1538–1544.PubMedGoogle Scholar
  129. 129.
    Hersh EM. Immunomodulatory drugs of relevance to the management of microbial infections. Adv Exp Med Biol 1992:319:1–11.PubMedGoogle Scholar
  130. 130.
    Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319–324.PubMedGoogle Scholar
  131. 131.
    Maiche AG, Muhonen T. Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients. Eur J Cancer 1993;29A:1403–1405.PubMedGoogle Scholar
  132. 132.
    Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316–322.PubMedGoogle Scholar
  133. 133.
    Gabrilove JL, Jakubowski A, Fain K. Grous J, Scher H, Sternberg C, Yagoda A, Clarkson B, Bonilla MA, Oettgen HF, Alton K, Boone T, Altrock B, Weite K, Souza L. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988;82:1454–1461.PubMedGoogle Scholar
  134. 134.
    Gabrilove JL, Jakubowski A, Scher H. Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MAS, Clarkson B, Oettgen HF, Alton K, Weite K, Souza L. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988:318:1414–1422.PubMedGoogle Scholar
  135. 135.
    Biesma B, de Vries EG, Willemse PH, Sluiter WJ, Postmus PE, Limburg PC, Stern AC, Vellenga E. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. Eur J Cancer 1990;26:932–936.PubMedGoogle Scholar
  136. 136.
    Walsh TJ. Invasive pulmonary aspergillosis in patients with neoplastic diseases. Semin Respir Infect 1990;5:111–122.PubMedGoogle Scholar
  137. 137.
    Walsh TJ, Lee JW, Roilides E. Pizzo PA. Recent progress and current problems in management of invasive fungal infections in patients with neoplastic diseases. Curr Opin Oncol 1992:4:647–655.PubMedGoogle Scholar
  138. 138.
    Weinberger M, Elattar I. Marshall D, Steinberg SM, Redner RL, Young NS, Pizzo PA. Patterns of infections in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine 1992;71:24–42.PubMedGoogle Scholar
  139. 139.
    Walsh TJ, Hiemenz J, Pizzo PA. Editorial response: Evolving risk factors for invasive fungal infections — All neutropenic patients are not the same. Clin Infect Dis 1994;18:793–798.PubMedGoogle Scholar
  140. 140.
    Walsh TJ. Management of immunocompromised patients with evidence of invasive mycosis. Hematolit/Oncol Clini North Am 1993;7:1003–1026.Google Scholar
  141. 141.
    Roilides E, Sein T, Holmes A, Chanock S, Blake C, Pizzo PA, Walsh TJ. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Infect Dis 1995;172:1028–1034.PubMedGoogle Scholar
  142. 142.
    Naparstek E. Granulocyte colony-stimulating factor, congenital neutropenia, and acute myeloid leukemia. N Engl J Med 1995;333:516–518.PubMedGoogle Scholar
  143. 143.
    Vellenga E, Young DC, Wagner K, Wiper D, Ostapovicz D, Griffin JD. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 1987:69:1771–1776.PubMedGoogle Scholar
  144. 144.
    Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990;4:826–834.PubMedGoogle Scholar
  145. 145.
    Aglietta M, Piacibello W. Sanavio F, Stacchini A, Apra F, Schena M, Mossetti C, Camino F, Caligaris-Cappio F, Gavosto F. Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. J Clin Invest 1989;83:551–557.PubMedGoogle Scholar
  146. 146.
    Hiddemann W, Kiehl M, Zuhlsdorf M, Busemann C, Schleyer E, Wormann B, Buchner T. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia. Semin Oncol 1992;19:31–37.PubMedGoogle Scholar
  147. 147.
    Smith MA, Singer CR, Pallister CJ, Smith JG. The effect of haemopoietic growth factors on the cell cycle of AML progenitors and their sensitivity to cytosine arabinoside in vitro. Br J Haematol 1995;90:767–773.PubMedGoogle Scholar
  148. 148.
    Motoji T, Watanabe M, Uzumaki H, Kusaka M, Fukamachi H, Shimosaka A, Oshimi K. Mizoguchi H. Granulocyte colony-stimulating factor (G-CSF) receptors on acute myeloblastic leukaemia cells and their relationship with the proliferative response to G-CSF in clonogenic assay. Br J Haematol 1991;77:54–59.PubMedGoogle Scholar
  149. 149.
    Dong F, Brynes RK. Tidow N, Weite K, Löwenberg B, Touw IP. Mutations in the gene for the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med 1995;333:487–493.PubMedGoogle Scholar
  150. 150.
    Marsoni S, Ungerleider RS, Hurson SB, Simon RM, Hammershaimb LD. Tolerance to antineoplastic agents in children and adults. Cancer Treat Rep 1985;69:1263–1269.PubMedGoogle Scholar
  151. 151.
    Fink FM, Maurer-Dengg K, Fritsch G, Mann G, Zoubek A, Falk M, Gadner H. Recombinant human granulocyte-macrophage colony-stimulating factor in septic neutropenic pediatric cancer patients: Detection of circulating hematopoietic precursor cells correlates with rapid granulocyte recovery. Med Pediatr Oncol 1995;25:365–371.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1998

Authors and Affiliations

  • Brigitta U. Mueller
  • Phillip A. Pizzo

There are no affiliations available

Personalised recommendations